Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington's disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics.

Feleus, Stephanie; van der Lee, Maaike; Swen, Jesse J; Roos, Raymund A C; de Bot, Susanne T

Feleus, Stephanie; van der Lee, Maaike; Swen, Jesse J; Roos, Raymund A C; de Bot, Susanne T.

Feleus S; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
van der Lee M; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Roos RAC; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
de Bot ST; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

Ther Adv Rare Dis ; 4: 26330040231204643, 2023.

Article en En | MEDLINE | ID: mdl-37955016

Palabras clave

Huntington's disease; biobank; drug type; medication efficacy; medication use; pharmacogenetics; pharmacogenomics; pharmacovigilance; protocol; rare disorder

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article